EQUITY RESEARCH – ANALYST MEETING

# **BANGKOK CHAIN HOSPITAL**

THAILAND / HEALTH CARE SERVICES

# FINANSIA FSS INTERNATIONAL INVESTMENT ADVISORY

# Key takeaways from analyst meeting

#### Highlights

- We have a neutral view from BCH's 1Q24 analyst meeting.
- International patient revenue declined by 6% y-y, mainly due to the 49% y-y plunge in Kuwait patient revenue (accounted for 4% of total revenue in 1Q24) following the Kuwaiti government's policy to cut payment guarantees for citizens seeking treatment overseas. Aside from Kuwait, revenue from patients from the UAE, Oman and Qatar (accounted for 2% of total revenue) grew by 24-57% y-y and CLMV (accounted for 6% of total revenue) also grew by 45% y-y.
- BCH is in talks with the Kuwait embassy to bring hospitals under BCH back to the payment guarantees list. However, the timeline is still uncertain.
- Management maintains their double-digit revenue growth target in 2024, despite growing 6% y-y in 1Q24. Key growth drivers are the opening of the Cancer Center in July, partially completing the renovation of KH Bangkae in June-24 and more SSO services, including sleep apnea treatments and check-up packages for 35year-old members. BCH also recently set up a new JV, Bangkok Chain Dental, to start mobile dental services in 3Q24.
- Accounts receivable (AR) outstanding for Covid treatments have decreased from THB421m in 4Q23 to THB318m in 1Q24 and UCEP expects to settle the remaining payment by Sep-24.
- SSO registered members grew by only 0.5% y-y to 1.02m in 1Q24 due to fewer members at KV Pathumthani, which is under renovation and being rebranded to KH (scheduled completion by Jan-25). However, management still expects the numbers to gradually increase throughout this year.
- Revenue growth in April is likely to be in the single digits from the low season and has accelerated in May.

#### **Recommendation and outlook**

- We maintain our 2024 core profit forecast of THB1.76b in 2024 (+25% y-y). Our forecast has a downside risk on the return of Kuwaiti patients, as we assume them to return in 3Q24.
- BCH trades at an attractive valuation of 28x 2024E P/E, relatively in line with its 5-year average. Share price catalysts would be strong earnings growth in 2024 premised on the turnaround of three new hospitals and the reduction of one-off expenses, including FX loss and the UCEP Covid provision, which was booked in 2023.




Teerapol Udomvej, CFA Fundamental Investment Analyst on Securities; License no. 080523 teerapol.udo@fssia.com, +66 2646 9969

# TARGET PRICE THB25.00 CLOSE THB19.50 UP/DOWNSIDE +28.2% TP vs CONSENSUS +1.3%

### **KEY STOCK DATA**

BCH TB

YE Dec (THB m)	2023	2024E	2025E	2026E
Revenue	11,729	12,647	13,803	15,069
Net profit	1,406	1,756	2,027	2,333
EPS (THB)	0.56	0.70	0.81	0.94
vs Consensus (%)	-	(0.3)	(1.5)	3.5
EBITDA	2,802	3,263	3,661	4,102
Recurring net profit	1,406	1,756	2,027	2,333
Core EPS (THB)	0.56	0.70	0.81	0.94
EPS growth (%)	(53.7)	24.9	15.4	15.1
Core P/E (x)	34.6	27.7	24.0	20.8
Dividend yield (%)	2.6	1.8	2.0	2.3
EV/EBITDA (x)	17.5	14.8	12.8	11.1
Price/book (x)	3.9	3.6	3.3	3.1
Net debt/Equity (%)	(4.4)	(11.3)	(18.2)	(24.8)
ROE (%)	11.2	13.5	14.5	15.4




	0			
Fr	ee float	(%)		50
Ma	ajor sha	reholde	er	Chalerm Harnphanich (33%)
12	m high/	low (TH	HB)	23.80/16.60
lss	sued sha	ares (m	ı)	2,493.75

Sources: Bloomberg consensus; FSSIA estimates


PREPARED BY FSS INTERNATIONAL INVESTMENT ADVISORY SECURITIES CO LTD (FSSIA). ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES CAN BE FOUND AT THE END OF THIS REPORT

#### Exhibit 1: Non-Covid general patient revenue




Source: BCH






Source: BCH

#### Exhibit 5: EBITDA margin




Note: 3Q22 excludes Moderna write-off Source: BCH

#### Exhibit 2: SSO revenue, quarterly




Source: BCH





Source: BCH

#### Exhibit 6: Core profit



Source: BCH

## **Financial Statements**

Bangkok Chain Hospital

Profit and Loss (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
Revenue	18,827	11,729	12,647	13,803	15,069
Cost of goods sold	(12,772)	(8,116)	(8,545)	(9,219)	(9,965)
Gross profit	6,055	3,613	4,102	4,584	5,104
Other operating income	-	-	-	-	-
Operating costs	(1,946)	(1,755)	(1,821)	(1,957)	(2,092)
Operating EBITDA	5,059	2,802	3,263	3,661	4,102
Depreciation	(950)	(944)	(982)	(1,034)	(1,090)
Goodwill amortisation	-	-	-	-	-
Operating EBIT	4,109	1,859	2,280	2,627	3,012
Net financing costs	(148)	(77)	(37)	(34)	(26)
Associates	0	1	1	1	1
Recurring non-operating income	84	102	106	111	117
Non-recurring items	0	0	0	0	0
Profit before tax	4,046	1,883	2,349	2,704	3,103
Тах	(888)	(405)	(470)	(541)	(620)
Profit after tax	3,157	1,479	1,879	2,163	2,483
Minority interests	(118)	(73)	(123)	(136)	(150)
Preferred dividends	-	-	-	-	-
Other items	-	-	-	-	-
Reported net profit	3,039	1,406	1,756	2,027	2,333
Non-recurring items & goodwill (net)	0	0	0	0	0
Recurring net profit	3,039	1,406	1,756	2,027	2,333
Per share (THB)					
Recurring EPS *	1.22	0.56	0.70	0.81	0.94
Reported EPS	1.22	0.56	0.70	0.81	0.94
DPS	1.40	0.50	0.35	0.39	0.45
Diluted shares (used to calculate per share data)	2,494	2,494	2,494	2,494	2,494
Growth					
Revenue (%)	(12.0)	(37.7)	7.8	9.1	9.2
Operating EBITDA (%)	(50.6)	(44.6)	16.4	12.2	12.1
Operating EBIT (%)	(56.2)	(54.8)	22.7	15.2	14.7
Recurring EPS (%)	(55.6)	(53.7)	24.9	15.4	15.1
Reported EPS (%)	(55.6)	(53.7)	24.9	15.4	15.1
Operating performance					
Gross margin inc. depreciation (%)	32.2	30.8	32.4	33.2	33.9
Gross margin exc. depreciation (%)	37.2	38.9	40.2	40.7	41.1
Operating EBITDA margin (%)	26.9	23.9	25.8	26.5	27.2
Operating EBIT margin (%)	21.8	15.8	18.0	19.0	20.0
Net margin (%)	16.1	12.0	13.9	14.7	15.5
Effective tax rate (%)	22.0	21.5	20.0	20.0	20.0
Dividend payout on recurring profit (%)	114.9	88.7	49.7	47.6	47.8
Interest cover (X)	28.4	25.4	63.7	80.1	121.5
Inventory days	12.3	17.0	15.2	15.0	15.0
Debtor days	49.3	37.0	24.2	22.2	20.3
Creditor days	41.0	67.9	67.8	67.0	66.9
Operating ROIC (%)	21.4	10.9	14.5	16.8	19.4
ROIC (%)	21.0	10.9	14.4	16.7	19.2
ROE (%)	23.9	11.2	13.5	14.5	15.4
ROA (%)	14.2	8.2	10.5	11.4	12.1
* Pre exceptional, pre-goodwill and fully diluted					
Revenue by Division (THB m)	2022	2023	2024E	2025E	2026E
Cash patient revenue	9,372	7,976	8,504	9,195	9,943
SSO patient revenue	3,371	3,850	4,142	4,608	5,126
NHSO patient revenue	6,084	(97)	0	0	0

Sources: Bangkok Chain Hospital; FSSIA estimates

# **Financial Statements**

Developer	01	Line and the L	
Bangkok	Chain	Hospital	

Cash Flow (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
Recurring net profit	3,039	1,406	1,756	2,027	2,333
Depreciation	950	944	982	1,034	1,090
Associates & minorities	-	-	-	-	
Other non-cash items	24	114	117	136	150
Change in working capital	1,459	1,563	9	31	35
Cash flow from operations	5,471	4,027	2,865	3,228	3,608
Capex - maintenance	(984)	(896)	(879)	(966)	(1,055)
Capex - new investment	-	-	-	-	
let acquisitions & disposals	2	4	0	0	(
Other investments (net)	-	-	-	-	
Cash flow from investing	(982)	(892)	(879)	(966)	(1,055
Dividends paid	(3,491)	(1,247)	(873)	(966)	(1,115)
quity finance	0	0	0	0	(
Debt finance	(3,153)	(2,310)	(200)	0	(00)
Other financing cash flows	(462)	(32)	(68)	(75)	(82)
cash flow from financing	(7,106)	(3,590)	(1,141)	(1,041)	(1,197)
lon-recurring cash flows	-	-	-	-	
Other adjustments	0 <b>0</b>	0 0	0	0 <b>0</b>	(
let other adjustments			0		
lovement in cash	(2,616)	(455)	845	1,221	1,356
ree cash flow to firm (FCFF)	4,645.31	3,230.18	2,038.56	2,317.13	2,608.09
ree cash flow to equity (FCFE)	875.07	791.94	1,718.22	2,187.08	2,470.54
er share (THB)					
CFF per share	1.86	1.30	0.82	0.93	1.05
CFE per share	0.35	0.32	0.69	0.88	0.99
tecurring cash flow per share	1.61	0.99	1.14	1.28	1.43
alance Sheet (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
angible fixed assets (gross)	20,274	20,884	21,769	22,735	23,790
ess: Accumulated depreciation	(7,992)	(8,639)	(9,622)	(10,655)	(11,745
angible fixed assets (net)	12,282	12,244	12,147	12,080	12,04
ntangible fixed assets (net)	425	440	440	440	44
ong-term financial assets		-	-	-	
ivest. in associates & subsidiaries	32	28	28	28	28
ash & equivalents	2,640	2,185	3,031	4,252	5,607
/C receivable	1,539	839	839	839	839
iventories	362	306	322	349	378
Other current assets	2,294	1,513	1,631	1,780	1,943
Current assets	6,835	4,843	5,823	7,220	8,768
Other assets	223	176	176	176	176
otal assets	19,796	17,731	18,614	19,943	21,457
Common equity	12,445	12,594	13,477	14,539	15,757
Ainorities etc.	1,065	1,110	1,166	1,227	1,295
otal shareholders' equity	13,510	13,704	14,643	15,766	17,051
ong term debt	3,888	1,497	1,297	1,297	1,297
ther long-term liabilities	163	187	187	187	187
ong-term liabilities	4,051	1,684	1,484	1,484	1,484
√C payable	1,300	1,368	1,464 1,442	1,561	1,693
Short term debt	1,300	81	81	81	1,693
Other current liabilities	935	894	964	1,052	
urrent liabilities				1,052 2,694	1,148
urrent liabilities otal liabilities and shareholders' equity	2,235 19 796	2,342 17 731	2,487 18 614	-	2,922 21 45
	<b>19,796</b>	17,731	18,614 387	<b>19,943</b>	21,45
et working capital wested capital	1,959 14,921	396 13,284	387 13,178	356 13,079	320 13,009
Includes convertibles and preferred stock which is be		10,204	13,170	13,079	13,005
· · · · · · · · · · · · · · · · · · ·					
er share (THB)	4.00	5.05	F 10	E 00	0.01
ook value per share angible book value per share	4.99 4.82	5.05 4.87	5.40 5.23	5.83 5.65	6.32 6.14
inancial strength	4.02	4.07	0.23	5.05	0.14
-	0.0	(A A)	(11.0)	(10.0)	(04.0
et debt/equity (%)	9.2	(4.4)	(11.3)	(18.2)	(24.8
et debt/total assets (%)	6.3	(3.4)	(8.9)	(14.4)	(19.7
urrent ratio (x)	3.1	2.1 11.3	2.3	2.7	3.0
F interest cover (x)	6.9	11.3	46.9	65.0	96.9
aluation	2022	2023	2024E	2025E	20268
ecurring P/E (x) *	16.0	34.6	27.7	24.0	20.8
ecurring P/E @ target price (x) *	20.5	44.3	35.5	30.8	26.
eported P/E (x)	16.0	34.6	27.7	24.0	20.8
ividend yield (%)	7.2	2.6	1.8	2.0	2.3
rice/book (x)	3.9	3.9	3.6	3.3	3.1
rice/tangible book (x)	4.0	4.0	3.7	3.4	3.:
V/EBITDA (x) **	10.1	17.5	14.8	12.8	11.1
	12.8	22.4	19.0	16.6	14.
V/EBITDA @ target price (x) **	12.0				
EV/EBITDA @ target price (x) ** EV/invested capital (x)	3.4	3.7	3.7	3.6	3.5

Sources: Bangkok Chain Hospital; FSSIA estimates



# Bangkok Chain Hospital PCL (BCH TB)



 $\star \star \star$ 

39.71 /100

#### Exhibit 7: FSSIA ESG score implication

Score	Implication
>79-100	Leading its industry peers in managing the most significant ESG risks which not only better cost efficiency but also lead to higher profitability.
>59-79	A mixed track record of managing the most significant ESG risks and opportunities relative to industry peers.
>39-59	Relevant ESG materiality matrix has been constructively addressed, well-managed and incorporated into day-to-day operations, in which targets and achievements are evaluated annually.
>19-39	Relevant ESG materiality matrix has been identified with key management in charge for progress to be followed up on and to provide intensive disclosure. Most targets are conventional and achievable.
1-19	The company has adopted the United Nations Sustainable Development Goals (UN SDGs), established sustainability management guidelines and fully complies with regulations or ESG suggested guidance from related organizations such as the SET and SEC.
	>79-100 >59-79 <b>&gt;39-59</b> >19-39

Sources: FSSIA estimates

#### Exhibit 8: ESG – peer comparison

	FSSIA			Domes	stic ratings	;				Glo	bal ratings	;		Bloomberg	
	ESG score	DJSI	SET THSI	THSI	CG score	AGM level	Thai CAC	Morningstar ESG risk	ESG Book	MSCI	Moody's	Refinitiv	S&P Global	ESG score	Disclosure score
SET100	69.20	5.34	4.40	4.40	4.76	4.65	3.84	Medium	51.76	BBB	20.87	58.72	63.91	3.72	28.17
Coverage	67.12	5.11	4.15	4.17	4.83	4.71	3.53	Medium	52.04	BB	16.97	56.85	62.09	3.40	31.94
BCH	39.71				4.00	5.00	Certified	High	48.21			27.19	18.00	3.52	47.60
BDMS	74.00	Y	Y	Y	5.00	4.00		Medium	61.06	AA	34.00	59.83	72.00	3.45	58.92
BH	51.21				4.00	4.00		Medium	64.29	Α	29.00	59.03	27.00	5.08	47.79
CHG	38.25				4.00	5.00		High	55.35			59.57	21.00	2.34	50.24
PR9	54.08		Y	Y	5.00	5.00	Certified	High	71.12			62.39		2.43	37.90
PRINC	18.00				4.00	4.00	Certified								
RAM	11.75				3.00			High							
THG	18.75				5.00	5.00		High							
VIBHA	20.88				4.00	3.00	Declared	High					17.00		

Sources: <u>SETTRADE.com</u>; FSSIA's compilation

#### Exhibit 9: ESG score by Bloomberg

FY ending Dec 31	FY 2015	FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022
ESG financial materiality scores - ESG score	0.56	0.71	0.75	0.72	0.80	0.85	2.36	3.52
BESG environmental pillar score	0.00	0.00	0.00	0.00	0.38	0.38	2.96	4.63
BESG social pillar score	0.00	0.22	0.22	0.22	0.22	0.22	1.70	3.47
BESG governance pillar score	2.35	2.41	2.62	2.50	2.41	2.63	3.19	2.91
ESG disclosure score	18.06	19.81	19.81	19.81	20.08	20.08	31.27	47.60
Environmental disclosure score	0.00	0.42	0.42	0.42	1.24	1.24	20.57	46.18
Social disclosure score	3.17	10.52	10.52	10.52	10.52	10.52	18.53	41.96
Governance disclosure score	50.87	48.37	48.37	48.37	48.37	48.37	54.64	54.64
Environmental								
Emissions reduction initiatives	No	No	No	No	Yes	Yes	Yes	Yes
Climate change policy	No	No	No	No	No	No	Yes	Yes
Climate change opportunities discussed	No							
Risks of climate change discussed	No							
GHG scope 1	—	—	—	—	—	—	1	2
GHG scope 2 location-based	—	—	—	—	—	—	5	6
GHG Scope 3	—	—	—	—	—	—	_	_
Carbon per unit of production	—	_	_	_	_	_	_	_
Biodiversity policy	No							
Energy efficiency policy	No	Yes						
Total energy consumption	—	—	—	—	—	—	10	12
Renewable energy use	_	_	_	_	_	_	_	_
Electricity used	_	_	_	_	_	_	10	12
Fuel used - natural gas	—	_	_	_	_	_	_	_

Sources: Bloomberg; FSSIA's compilation

#### Exhibit 10: ESG score by Bloomberg (cont.)

FY ending Dec 31	FY 2015	FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022
Fuel used - crude oil/diesel	No							
Waste reduction policy	No	No	No	No	Yes	Yes	Yes	Yes
Hazardous waste	_	—	_	_	_	—	—	0
Total waste	_	—	—	—	_	_	_	0
Waste recycled	_	—	—	—	_	_	_	0
Waste sent to landfills	—	—	—	—	—	_	—	0
Environmental supply chain management	No	Yes						
Water policy	No	No	No	No	No	No	Yes	Yes
Water consumption	-	-	_	_	-	-	_	_
Social								
Human rights policy	No	Yes						
Policy against child labor	No	Yes						
Quality assurance and recall policy	No	Yes						
Consumer data protection policy	No							
Equal opportunity policy	Yes							
Gender pay gap breakout	No							
Pct women in workforce	—	—	—	—	—	-	—	76
Pct disabled in workforce	—	—	—	—	—	—	—	1
Business ethics policy	Yes							
Anti-bribery ethics policy	No	Yes						
Health and safety policy	No	Yes						
Lost time incident rate - employees	_	_	_	_	_	_	0	0
Total recordable incident rate - employees	_	—	_	_	_	-	0	1
Training policy	No	Yes						
Fair remuneration policy	No	Yes						
Number of employees – CSR	—	—	—	—	—	—	8,597	8,877
Employee turnover pct	—	—	—	—	—	—	—	43
Total hours spent by firm - employee training	—	—	—	—	—	—	—	54,702
Social supply chain management	No	Yes						
Governance								
Board size	10	10	10	12	12	12	12	11
No. of independent directors (ID)	4	4	4	4	4	4	4	4
No. of women on board	3	3	3	4	4	3	3	3
No. of non-executive directors on board	5	5	5	5	5	5	5	5
Company conducts board evaluations	Yes							
No. of board meetings for the year	6	5	6	5	5	6	6	6
Board meeting attendance pct	93	94	90	96	100	99	94	97
Board duration (years)	_	—	—	—	—	_	_	_
Director share ownership guidelines	No							
Age of the youngest director	28	29	30	29	30	31	32	33
Age of the oldest director	72	73	74	75	76	77	78	79
No. of executives / company managers	5	5	5	5	5	7	7	6
No. of female executives	1	_	_	_	_	_	_	_
Executive share ownership guidelines	No							
Size of audit committee	3	3	3	3	3	3	3	3
No. of ID on audit committee	3	3	3	3	3	3	3	3
Audit committee meetings	4	4	5	5	5	5	5	5
Audit meeting attendance %	100	92	100	93	100	100	93	100
Size of compensation committee	0	0	0	0	0	0	0	0
No. of ID on compensation committee	_	_	_	_	_	_	_	_
No. of compensation committee meetings	_	_	_	_	_	_	_	_
Compensation meeting attendance %	_	_	_	_	_	_	_	_
Size of nomination committee	0	0	0	0	0	0	0	0
No. of nomination committee meetings	_	_	_	_	_	_	_	_
Nomination meeting attendance %	_	_	_	_	_	_	_	_
Sustainability governance								

Sources: Bloomberg; FSSIA's compilation

#### **Disclaimer for ESG scoring**

ESG score	Methodology				Rating						
The Dow Jones Sustainability Indices (DJSI) By S&P Global	process base from the annu Only the top-r inclusion.	d on the con al S&P Glob anked comp	transparent, rules-based npanies' Total Sustainabi pal Corporate Sustainabil panies within each industr	ility Scores resulting ity Assessment (CSA). ry are selected for	Be a member and invited to the annual S&P Global Corporate Sustainability Assessment (CSA) for DJSI. Companies with an S&P Global ESG Score of less than 45% of the S&P Global ESG Score of the highest scoring company are disqualified. The constituents of the DJSI indices are selected from the Eligible Universe.						
Sustainability Investment List ( <u>THSI</u> ) by The Stock Exchange of Thailand ( <u>SET</u> )	managing bus Candidates m 1) no irregula float of >150 s up capital. So 70%; 2) indep wrongdoing re	siness with tu ust pass the trading of th shareholders me key disq endent direct elated to CG	ility in Environmental and ransparency in Governan e preemptive criteria, with he board members and e s, and combined holding i ualifying criteria include: ctors and free float violati i, social & environmental earnings in red for > 3 yes	ace, updated annually. a two crucial conditions: executives; and 2) free must be >15% of paid- 1) CG score of below on; 3) executives' impacts; 4) equity in	To be eligible for <u>THSI inclusion</u> , verified data must be scored at a minimum of 50% for each indicator, unless the company is a part of DJSI during the assessment year. The scoring will be fairly weighted against the nature of the relevant industry and materiality. <u>SETTHSI Index</u> is extended from the THSI companies whose 1) market capitalization > THB5b (-USD150b); 2) free float >20%; and 3) liquidity >0.5% of paid-up capital for at least 9 out of 12 months. The SETTHSI Index is a market capitalisation-weighted index, cap 5% quarterly weight a maximum, and no cap for number of stocks.						
CG Score by Thai Institute of Directors Association (Thai IOD)	annually by th	e Thai IOD, Γ). The resul	th in sustainable develop with support from the St Its are from the perspecti Is.	ock Exchange of	Good (80-89), 3 and not rated for equitable treatm	for Good (70 r scores below ent of shareh 5%); 4) disclos	ories: 5 for Excell -79), 2 for Fair (6 w 50. Weightings olders (weight 2 sure & transpare	60-69), 1 for P include: 1) th 5% combined)	ass (60-69), e rights; 2) and ); 3) the role of		
AGM level By Thai Investors Association (TIA) with support from the SEC	treatment are transparent a out of five the criteria cover date (45%), a <i>circulation of su</i> <i>exercised. The</i> <i>and verifiability;</i>	incorporate nd sufficient CG compor AGM proceed nd after the fficient informa second assess and 3) openno	which shareholders' right: d into business operation ly disclosed. All form impu- nents to be evaluated anr dures before the meeting meeting (10%). (The first a ation for voting; and 2) facilita ses 1) the ease of attending n ess for Q&A. The third involve use, resolutions and voting re	s and information is ortant elements of two nually. The assessment (45%), at the meeting assesses 1) advance ting how voting rights can be neetings; 2) transparency es the meeting minutes that	be						
Thai CAC By Thai Private Sector Collective Action Against Corruption (CAC)	establishmen policies. The (Companies de Declaration of li Certification, ind managers and e	t of key cont Certification ciding to becont tent to kick of cluding risk ass employees, es	Checklist include corrupti rols, and the monitoring a is good for three years. me a CAC certified member s ff an 18-month deadline to su sessment, in place of policy a tablishment of whistleblowing all stakeholders.)	and developing of start by submitting a bmit the CAC Checklist for and control, training of	The document will be reviewed by a committee of nine professionals. A passed Checklist will move for granting certification by the CAC Council approvals whose members are twelve highly respected individuals in professionalism and ethical achievements.						
<u>Morningstar</u> Sustainalytics	based on an a risk is unman regulatory filing	assessment aged. Source s, news and ot	isk rating provides an ove of how much of a compa so to be reviewed include corp ther media, NGO reports/web	ny's exposure to ESG porate publications and posites, multi-sector	more risk is unn	nanaged, the	score is the sum higher ESG risk i	is scored.			
	information, cor reports, and qua		ck, ESG controversies, issuer views.	feedback on draft ESG	0-10	Low 10-20	<b>Medium</b> 20-30	High 30-40	Severe 40+		
ESG Book	positioned to the principle on helps explain	outperform o of financial m future risk-a g features w	sustainable companies the over the long term. The me hateriality including inform djusted performance. Ma ith higher materiality and erly basis.	nethodology considers nation that significantly ateriality is applied by	The total ESG s	core is calculateriality-base	ated as a weighted d weights. The s dicating better pe	core is scaled			
<u>MSCI</u>	MSCI ESG ra	tings aim to ry leaders a	measure a company's m nd laggards according to	anagement of financially their exposure to ESG ris	relevant ESG risk sks and how well	s and opportu they manage	unities. It uses a those risks relati	rules-based m ve to peers.	nethodology to		
	AAA AA	8.571-10.00 7.143-8.57	Leader:	leading its industry in m	anaging the most sig	gnificant ESG ris	sks and opportunitie	s			
	A BBB	5.714-7.14 4.286-5.71	3 Average:	a mixed or unexception industry peers	al track record of ma	naging the most	t significant ESG ris	ks and opportur	nities relative to		
	BB B CCC	BB       2.857-4.285         B       1.429-2.856         Laggard:       lagging its industry based on its high exposure and failure to manage significant ESG risks									
Moody's ESG solutions	Moody's asserted believes that	a company i	gree to which companies	take into account ESG of to its business model and medium to long term.							
	Designed to t			e a company's relative ES e score ranges from 0 to	100 on relative ES	SG performan	ce and insufficier	nt degree of tr			
Refinitiv ESG rating	based on pub			are 0 to 25 = poor; >25 to 50 =	- salisiaciory, >50 lo			iieni.)			
Refinitiv ESG rating S&P Global	based on pub reporting mat	erial ESG da bal ESG Sco	ata publicly. (Score ratings a pre is a relative score mea	are 0 to 25 = poor; >25 to 50 = asuring a company's perf ssification. The score rang	ormance on and		of ESG risks, opp	,	d impacts		
rating	based on pub reporting mat	erial ESG da bal ESG Sco	ata publicly. (Score ratings of ore is a relative score mean hin the same industry class Bloomberg score evalue score is based on Bloo	asuring a company's perf	ormance on and i ges from 0 to 100 regated Environm incial materiality.	ental, Social a The score is a	and Governance a weighted gener	(ESG) performalized mean (	mance. The power mean)		

Rating regarding the sustainable development of Thai listed companies, both on the SET and MAI, are publicly available on the website of the Securities and Exchange Commission of Thailand (SEC). Currently, ratings available are 1) "CG Score"; 2) "AGM Level"; 3) "Thai CAC"; and 4) THSI. The ratings are updated on an annual basis. FSSIA does not confirm nor certify the accuracy of such ratings. Source: FSSIA's compilation

#### **GENERAL DISCLAIMER**

#### ANALYST(S) CERTIFICATION

#### Teerapol Udomvej, CFA FSS International Investment Advisory Securities Co., Ltd

The individual(s) identified above certify(ies) that (i) all views expressed in this report accurately reflect the personal view of the analyst(s) with regard to any and all of the subject securities, companies or issuers mentioned in this report; and (ii) no part of the compensation of the analyst(s) was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed herein.

This report has been prepared by FSS International Investment Advisory Securities Company Limited (FSSIA). The information herein has been obtained from sources believed to be reliable and accurate; however FSSIA makes no representation as to the accuracy and completeness of such information. Information and opinions expressed herein are subject to change without notice. FSSIA has no intention to solicit investors to buy or sell any security in this report. In addition, FSSIA does not guarantee returns nor price of the securities described in the report nor accept any liability for any loss or damage of any kind arising out of the use of such information or opinions in this report. Investors should study this report carefully in making investment decisions. All rights are reserved.

This report may not be reproduced, distributed or published by any person in any manner for any purpose without permission of FSSIA. Investment in securities has risks. Investors are advised to consider carefully before making investment decisions.

#### History of change in investment rating and/or target price



Teerapol Udomvej, CFA started covering this stock from 30-Jul-2020

26 00

03-Aug-2023

BUY

Price and TP are in local currency

Source: FSSIA estimates

25-Oct-2022

Company	Ticker	Price	Rating	Valuation & Risks
Bangkok Chain Hospital	BCH TB	THB 19.50	BUY	Downside risks to our DCF-based target price include 1) a slowdown in international patients due to economic concerns, political protests or floods; 2) regulatory risks from drug prices and medical bill controls; and 3) SSO provision expenses following a limited SSO budget.

BUY

22 50

29-Apr-2024

BUY

25 00

Source: FSSIA estimates

#### Additional Disclosures

Target price history, stock price charts, valuation and risk details, and equity rating histories applicable to each company rated in this report is available in our most recently published reports. You can contact the analyst named on the front of this note or your representative at Finansia Syrus Securities Public Company Limited.

All share prices are as at market close on 27-May-2024 unless otherwise stated.



#### **RECOMMENDATION STRUCTURE**

#### Stock ratings

Stock ratings are based on absolute upside or downside, which we define as (target price\* - current price) / current price.

BUY (B). The upside is 10% or more.

HOLD (H). The upside or downside is less than 10%.

REDUCE (R). The downside is 10% or more.

Unless otherwise specified, these recommendations are set with a 12-month horizon. Thus, it is possible that future price volatility may cause a temporary mismatch between upside/downside for a stock based on market price and the formal recommendation.

\* In most cases, the target price will equal the analyst's assessment of the current fair value of the stock. However, if the analyst doesn't think the market will reassess the stock over the specified time horizon due to a lack of events or catalysts, then the target price may differ from fair value. In most cases, therefore, our recommendation is an assessment of the mismatch between current market price and our assessment of current fair value.

#### **Industry Recommendations**

**Overweight.** The analyst expects the fundamental conditions of the sector to be positive over the next 12 months. **Neutral.** The analyst expects the fundamental conditions of the sector to be maintained over the next 12 months. **Underweight.** The analyst expects the fundamental conditions of the sector to be negative over the next 12 months.

#### **Country (Strategy) Recommendations**

**Overweight (O).** Over the next 12 months, the analyst expects the market to score positively on two or more of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Neutral (N). Over the next 12 months, the analyst expects the market to score positively on one of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Underweight (U). Over the next 12 months, the analyst does not expect the market to score positively on any of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.